Trial Profile
Randomized, double blinded, crossover study to evaluate safety and pharmacokinetic/pharmacodynamic characteristics of PDA10 (recombinant human epoetin-alfa) compare to Eprex in healthy male volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Sep 2019
Price :
$35
*
At a glance
- Drugs Erythropoietin (Primary)
- Indications Anaemia
- Focus Pharmacokinetics
- Acronyms PG-EPO-Ph1
- 14 Sep 2015 Results published in the Clinical Drug Investigation.
- 08 Jun 2015 New trial record